Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis
ABSTRACT Aims: To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods: A post hoc patient-level metaanalysis using data from th...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/16093/1/69.pdf |
| _version_ | 1824414494880694272 |
|---|---|
| author | Twigg, Stephen M. Escalada, Javier Stella, Peter Merino Trigo, Ana Lavalle González, Fernando Javier Cariou, Bertrand Meneghini, Luigi F. |
| author_facet | Twigg, Stephen M. Escalada, Javier Stella, Peter Merino Trigo, Ana Lavalle González, Fernando Javier Cariou, Bertrand Meneghini, Luigi F. |
| author_sort | Twigg, Stephen M. |
| collection | Repositorio Institucional |
| description | ABSTRACT
Aims: To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods: A post hoc patient-level metaanalysis using data from three multicenter, randomized, open-label, parallel-group, phase 3a studies of similar design, in people previously receiving either basal and prandial insulin, basal
insulin ? oral antihyperglycemic drugs, or no prior insulin (EDITION 1, 2 and 3, respectively). The endpoints, glycated hemoglobin (HbA1c), hypoglycemia, body weight change, and insulin dose were investigated by subgroups: age (\65 and C 65 years), body mass index (BMI; \ 30 and C 30 kg/m2), age at onset (\40, 40–50, and [ 50 years), and diabetes duration (\ 10 and C 10 years). Results: Reduction in HbA1c was comparable between insulins, regardless of subgroup. The lower risk of C 1 nocturnal (00:00–05:59 h) confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemic event with Gla-300 versus Gla-100 was also unaffected by participant characteristics. While heterogeneity of treatment effect between diabetes duration subgroups was seen for the risk of C 1 confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemic event at any time (24 h), treatment effect consistently favored Gla-300; no evidence of heterogeneity was observed for the other subgroups. Annualized rates of confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemia and body weight change were not influenced by participant characteristics; a similar pattern was observed with insulin dose. Conclusions: Comparable glycemic control was observed with Gla-300 versus Gla-100, with less hypoglycemia, regardless of age, BMI, age at onset or diabetes duration. Funding: Sanofi. Plain Language Summary: Plain language summary available for this article.
Keywords: Glycated Hemoglobin A; Hypoglycemia; Insulin Glargine; Type 2 Diabetes
PLAIN LANGUAGE SUMMARY
Treatments for patients with type 2 diabetes aim to reduce the levels of blood glucose and can include injections with insulin. However, care must be taken to prevent blood glucose levels falling too low (a state called hypoglycemia). Previous studies have shown that insulin glargine 300 units/mL (Gla-300) provides similar reductions in blood glucose levels as insulin glargine 100 units/mL (Gla-100) but is less likely to cause hypoglycemia. However, different patients may respond differently to treatments depending on their individual clinical and biological characteristics. The aim of this study was to evaluate how different profiles of patients with type 2 diabetes responded to Gla-300 and Gla-100 injections. Patients were grouped by different ages, weights, age at diabetes diagnosis, and number of years since diagnosis of diabetes. We found that Gla-300 and Gla-100 reduced glycated hemoglobin (HbA1c; a marker of blood glucose control over the previous 2–3 months) similarly, regardless of how patients were grouped. However, patients treated with Gla-300 were less likely to experience hypoglycemia than those treated with Gla-100, and this association was also true regardless of different patient characteristics. We therefore concluded that Gla-300 is an effective and safe treatment in patients with type 2 diabetes,
regardless of their age, weight, age at diabetes diagnosis, and years since diagnosis. |
| format | Article |
| id | eprints-16093 |
| institution | UANL |
| language | English |
| publishDate | 2018 |
| record_format | eprints |
| spelling | eprints-160932024-03-05T15:35:46Z http://eprints.uanl.mx/16093/ Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis Twigg, Stephen M. Escalada, Javier Stella, Peter Merino Trigo, Ana Lavalle González, Fernando Javier Cariou, Bertrand Meneghini, Luigi F. RC Medicina Interna, Psiquiatría, Neurología ABSTRACT Aims: To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods: A post hoc patient-level metaanalysis using data from three multicenter, randomized, open-label, parallel-group, phase 3a studies of similar design, in people previously receiving either basal and prandial insulin, basal insulin ? oral antihyperglycemic drugs, or no prior insulin (EDITION 1, 2 and 3, respectively). The endpoints, glycated hemoglobin (HbA1c), hypoglycemia, body weight change, and insulin dose were investigated by subgroups: age (\65 and C 65 years), body mass index (BMI; \ 30 and C 30 kg/m2), age at onset (\40, 40–50, and [ 50 years), and diabetes duration (\ 10 and C 10 years). Results: Reduction in HbA1c was comparable between insulins, regardless of subgroup. The lower risk of C 1 nocturnal (00:00–05:59 h) confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemic event with Gla-300 versus Gla-100 was also unaffected by participant characteristics. While heterogeneity of treatment effect between diabetes duration subgroups was seen for the risk of C 1 confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemic event at any time (24 h), treatment effect consistently favored Gla-300; no evidence of heterogeneity was observed for the other subgroups. Annualized rates of confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemia and body weight change were not influenced by participant characteristics; a similar pattern was observed with insulin dose. Conclusions: Comparable glycemic control was observed with Gla-300 versus Gla-100, with less hypoglycemia, regardless of age, BMI, age at onset or diabetes duration. Funding: Sanofi. Plain Language Summary: Plain language summary available for this article. Keywords: Glycated Hemoglobin A; Hypoglycemia; Insulin Glargine; Type 2 Diabetes PLAIN LANGUAGE SUMMARY Treatments for patients with type 2 diabetes aim to reduce the levels of blood glucose and can include injections with insulin. However, care must be taken to prevent blood glucose levels falling too low (a state called hypoglycemia). Previous studies have shown that insulin glargine 300 units/mL (Gla-300) provides similar reductions in blood glucose levels as insulin glargine 100 units/mL (Gla-100) but is less likely to cause hypoglycemia. However, different patients may respond differently to treatments depending on their individual clinical and biological characteristics. The aim of this study was to evaluate how different profiles of patients with type 2 diabetes responded to Gla-300 and Gla-100 injections. Patients were grouped by different ages, weights, age at diabetes diagnosis, and number of years since diagnosis of diabetes. We found that Gla-300 and Gla-100 reduced glycated hemoglobin (HbA1c; a marker of blood glucose control over the previous 2–3 months) similarly, regardless of how patients were grouped. However, patients treated with Gla-300 were less likely to experience hypoglycemia than those treated with Gla-100, and this association was also true regardless of different patient characteristics. We therefore concluded that Gla-300 is an effective and safe treatment in patients with type 2 diabetes, regardless of their age, weight, age at diabetes diagnosis, and years since diagnosis. 2018-09-10 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/16093/1/69.pdf http://eprints.uanl.mx/16093/1.haspreviewThumbnailVersion/69.pdf Twigg, Stephen M. y Escalada, Javier y Stella, Peter y Merino Trigo, Ana y Lavalle González, Fernando Javier y Cariou, Bertrand y Meneghini, Luigi F. (2018) Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. Diabetes Therapy, 9 (5). pp. 2043-2053. ISSN 1869-6953 http://doi.org/10.1007/s13300-018-0498-x doi:10.1007/s13300-018-0498-x |
| spellingShingle | RC Medicina Interna, Psiquiatría, Neurología Twigg, Stephen M. Escalada, Javier Stella, Peter Merino Trigo, Ana Lavalle González, Fernando Javier Cariou, Bertrand Meneghini, Luigi F. Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis |
| title_full | Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis |
| title_fullStr | Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis |
| title_full_unstemmed | Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis |
| title_short | Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis |
| title_sort | association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 u ml in type 2 diabetes a post hoc patient level meta analysis |
| topic | RC Medicina Interna, Psiquiatría, Neurología |
| url | http://eprints.uanl.mx/16093/1/69.pdf |
| work_keys_str_mv | AT twiggstephenm associationofpatientprofilewithglycemiccontrolandhypoglycemiawithinsulinglargine300umlintype2diabetesaposthocpatientlevelmetaanalysis AT escaladajavier associationofpatientprofilewithglycemiccontrolandhypoglycemiawithinsulinglargine300umlintype2diabetesaposthocpatientlevelmetaanalysis AT stellapeter associationofpatientprofilewithglycemiccontrolandhypoglycemiawithinsulinglargine300umlintype2diabetesaposthocpatientlevelmetaanalysis AT merinotrigoana associationofpatientprofilewithglycemiccontrolandhypoglycemiawithinsulinglargine300umlintype2diabetesaposthocpatientlevelmetaanalysis AT lavallegonzalezfernandojavier associationofpatientprofilewithglycemiccontrolandhypoglycemiawithinsulinglargine300umlintype2diabetesaposthocpatientlevelmetaanalysis AT carioubertrand associationofpatientprofilewithglycemiccontrolandhypoglycemiawithinsulinglargine300umlintype2diabetesaposthocpatientlevelmetaanalysis AT meneghiniluigif associationofpatientprofilewithglycemiccontrolandhypoglycemiawithinsulinglargine300umlintype2diabetesaposthocpatientlevelmetaanalysis |